$38MVenture, 6 May 2026
Funds advance the Phase 1 study of LTZ-301 in lymphoma and IND work for LTZ-232.
- Amount
- $38M
- Stage
- Venture
- Announced
- 6 May 2026
- Lead
- GL Ventures
- Use of funds
- Funds advance the Phase 1 study of LTZ-301 in lymphoma and IND work for LTZ-232.
- Checked
- Announced by the company
- Sources
- LTZ Therapeutics raises $38M for myeloid engager immunotherapy businesswire.com
LTZ Therapeutics raises $38M for myeloid engager immunotherapy pulse2.com